The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Thymidine phosphorylase expression is associated with time to progression in patients with metastatic colorectal cancer
Open accessAbstract
BACKGROUND: 5-Fluorouracil (5-FU) is the cornerstone of chemotherapeutic treatment for patients with colorectal cancer. The enzyme thymidine phosphorylase (TP) catalyzes the conversion of 5-FU to its active metabolite, 5-fluoro-2'-deoxyuridine. TP is expressed in tumour epithelial cells and stromal cells, particularly in tumour-associated macrophages. These macrophages may affect sensitivity to chemotherapy. Previously, we identified TP as a predictive factor in microdissected tumour samples of patients with advanced colorectal cancer. In the present study, we analysed TP expression in tissues and associated stromal cells from patients with advanced colorectal cancer and associated TP levels to tumour response and time-to-event variables during first-line chemotherapy treatment. We also investigated the association between serum TP levels at the time of surgery and gene expression in primary tumour tissues. METHODS: This study included 125 patients with metastatic colorectal cancer treated with first-line 5-FU-based chemotherapy. To quantify TP gene expression levels in tumour tissues, real-time polymerase chain reaction was performed using the 7500 Fast Real-Time PCR system (Applied Biosystems, Foster City, CA, USA). TP protein concentration in matched serum samples was determined using an enzyme-linked immunosorbent assay system (USCN Life Science Inc.). RESULTS: The tumour response rate was 31%, and 30% of patients exhibited stable disease. No associations between TP expression level and age or gender were observed. Levels of TP mRNA in mucosa and tumours were positively correlated (r = 0.41, p < 0.01). No correlation between TP expression and tumour response rate was observed. Time to progression was significantly longer in patients with high TP expression (p < 0.01). Serum TP protein levels were not associated with tumour response or time-to-event variables and did not correlate with gene expression in tumour tissues. CONCLUSIONS: High TP gene expression in non-microdissected tumour tissues of patients with advanced colorectal cancer correlates with longer time to progression, which could be related to treatment. These results are in contrast to previous studies where microdissected tumour cells were analysed and may be due to the presence of adjacent stromal cells. Serum TP protein expression does not correlate to TP gene expression in tissues of patients with advanced colorectal cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“the progression-free survival of patients with higher expression of TP is significantly prolonged [11].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [11]
In the citing paper
“Although another study has shown that there is no correlation between the level of TP expression and tumor response rate”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [11]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PROTEIN MEASUREMENT WITH THE FOLIN PHENOL REAGENT
Lowry, O., Rosebrough, N., Farr, A. L., & Randall, R. (1951) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)52451-6 · Cited by 317,331
Reporting results of cancer treatment
Miller, A. B., Hoogstraten, B., Staquet, M., & Winkler, A. (1981) · Cancer · doi:10.1002/1097-0142(19810101)47:1<207::aid-cncr2820470134>3.0.co;2-6 · Cited by 7,793
Miwa, M., Ura, M., Nishida, M., Sawada, N., Ishikawa, T., Mori, K., Shimma, N., Umeda, I., & Ishitsuka, H. (1998) · European Journal of Cancer · doi:10.1016/s0959-8049(98)00058-6 · Cited by 1,240
(2011) · Hepatogastroenterology · doi:10.5754/hge11470 · Cited by 646
Takebayashi, Y., Akiyama, S.-I., Akiba, S., Yamada, K., Miyadera, K., Sumizawa, T., Yamada, Y., Murata, F., & Aikou, T. (1996) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/88.16.1110 · Cited by 363
Anti‐tumour strategies aiming to target tumour‐associated macrophages
Tang, X., Mo, C., Wang, Y., Wei, D., & Xiao, H. (2013) · Immunology · doi:10.1111/imm.12023 · Cited by 278
Metzger, R., Danenberg, K. D., Leichman, C. G., Salonga, D. S., Schwartz, E. L., Wadler, S., Lenz, H., Groshen, S. G., Leichman, L., & Danenberg, P. V. (1998) · PubMed · Cited by 259
The dual role of thymidine phosphorylase in cancer development and chemotherapy
Bronckaers, A., Gago, F., Balzarini, J., & Liekens, S. (2009) · Medicinal Research Reviews · doi:10.1002/med.20159 · Cited by 206
The activity and expression of thymidine phosphorylase in human solid tumours
Takebayashi, Y., Yamada, K., Miyadera, K., Sumizawa, T., Furukawa, T., Kinoshita, F., Aoki, D., Okumura, H., Yamada, Y., Akiyama, S.-I., et al. (1996) · European Journal of Cancer · doi:10.1016/0959-8049(96)00061-5 · Cited by 181
Expression of Macrophage Antigens by Tumor Cells
Shabo, I., & Svanvik, J. (2011) · Advances in experimental medicine and biology · doi:10.1007/978-94-007-0782-5_7 · Cited by 117
Research works printed but not linked: 1
- van Halteren HK, Peters HM, van Krieken JH, Coebergh JW, Roumen RM, van der Worp E, Wagener JT, Vreugdenhil G: Tumor growth pattern and thymidine phosphorylase expression are related with the risk of hematogenous metastasis in patients with Astler Coller B1/B2 colorectal carcinoma. Cancer. 2001, 91: 1752-1757. 10.1002/1097-0142(20010501)91:9<1752::AID-CNCR1194>3.0.CO;2-M. · doi:10.1002/1097-0142(20010501)91:9<1752::aid-cncr1194>3.0.co;2-m
Cited by
5-fluorouracil and other fluoropyrimidines in colorectal cancer: Past, present and future
Vodenkova, S., Buchler, T., Cervena, K., Veskrnova, V., Vodicka, P., & Vymetalkova, V. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.107447 · Cited by 956
Pharmacologic resistance in colorectal cancer: a review
Hammond, W. A., Swaika, A., & Mody, K. (2016) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834015614530 · Cited by 519
Drug Resistance in Colorectal Cancer: From Mechanism to Clinic
Wang, Q., Shen, X., Chen, G., & Du, J. (2022) · Cancers · doi:10.3390/cancers14122928 · Cited by 160
Bitar, S. A., El-Sabban, M. E., Doughan, S., & Abou-Kheir, W. G. (2023) · World Journal of Gastroenterology · doi:10.3748/wjg.v29.i9.1395 · Cited by 74
Albadari, N. G., Xie, Y., & Li, W. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1340401 · Cited by 37
Metadata
- Authors
- Lindskog, E. B., Derwinger, K., Gustavsson, B., Falk, P., & Wettergren, Y.
- Affiliations
- University of Gothenburg (SE)
- Corresponding author
- Lindskog, Elinor Bexe
- Venue
- BMC Clinical Pathology
- Published
- 2014-06-10
- Volume
- 14
- Issue
- 1
- Pages
- 25-25
- ISSN
- 1472-6890 (ISSN-L)
- PMC
- PMC4058433
- OpenAlex
- W2075758937
- Cited by
- 22
- References
- 36
- Citations by year
- 2024: 1 · 2023: 2 · 2022: 5 · 2021: 2 · 2019: 3 · 2018: 2 · 2017: 1 · 2016: 2 · 2015: 3 · 2014: 1
- FWCI
- 1.13
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- BMC Clinical Pathology (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- Anna-Lisa och Bror Björnssons Stiftelse
- Cancerfonden
- Stiftelsen Assar Gabrielssons Fond
- Göteborgs Läkaresällskap
- Sahlgrenska Universitetssjukhuset
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cancer therapeutics and mechanisms
- Keywords
- thymidine phosphorylase, metastatic colorectal cancer, 5-fluorouracil, time to progression, tumor stroma, tumour-associated macrophages, chemotherapy response, predictive biomarkers, first-line chemotherapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Thymidine phosphorylase expression is associated with time to progression in patients with metastatic colorectal cancer. https://app.cochat.ai/papers/10.1186/1472-6890-14-25
- The paper
- Lindskog, E. B., Derwinger, K., Gustavsson, B., Falk, P., & Wettergren, Y. (2014). Thymidine phosphorylase expression is associated with time to progression in patients with metastatic colorectal cancer. BMC Clinical Pathology. https://doi.org/10.1186/1472-6890-14-25
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
